Biotech Values

[mcbio]

ENTA

I interpret this to mean that the FXR target of ENTA’s preclinical drug has been “validated” by ICPT’s OCA; hence, if ENTA’s drug is somehow better than OCA, it could end up being a significant asset.

Has ENTA given guidance as to when they expect their NASH drug(s) to hit the clinic? Also, just curious if they've given any early inkling as to how they could be differentiated from the ICPT drug.